Assessing New Therapies for Retinal Diseases

Opinion
Video

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Video content above is prompted by the following:

  • New Therapies:
  • Aflibercept 8 mg
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Related Content
Systane Ultra PF voluntary recall: Protecting patients from potential risk of fungal material in one lot

Systane Ultra PF voluntary recall: Protecting patients from potential risk of fungal material in one lot

Lynda Charters;Sheryl Stevenson
December 27th 2024
Article

Alcon Laboratories is voluntarily recalling one lot (Lot 10101) of its Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after identifying fungal contamination in a sealed vial.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A picture of a scale on a laptop computer. One side of the scale holds a human brain, the other holds a laptop, symbolising artificial intelligence. Image credit: ©Who is Danny – stock.adobe.com

Balancing the promises and challenges of artificial intelligence

Polat Goktas, PhD;Andrzej Grzybowski, MD, PhD, MBA, MAE
December 18th 2024
Article

Sophisticated programmes require an evolving mindset

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A large vertical banner, indicating the headquarters of the European Commission, hanging on the southern wing of the Berlaymont building. Image credit: ©olrat – stock.adobe.com

European Commission grants marketing authorisation for aflibercept biosimilar Afqlir (Sandoz Group)

Sydney M Crago
November 15th 2024
Article

The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration

Bottles of essential oils are placed next to an essential oil aromatherapy diffuser in a calm, warm, spa-like environment. Image credit: ©Botamochy – stock.adobe.com

Adding aromatherapy to recovery protocol may decrease postoperative anxiety and pain

Lynda Charters
November 8th 2024
Article

Following oculoplastic surgery, patients who underwent aromatherapy had shorter stays in the post-anesthesia care unit

© 2025 MJH Life Sciences

All rights reserved.